
TY  - JOUR
TI  - American Association of Anatomists one hundred and fourth annual meeting
JO  - The Anatomical Record
JA  - Anat. Rec.
VL  - 229
IS  - 4
SN  - 0003-276X
UR  - https://doi.org/10.1002/ar.1092290418
DO  - doi:10.1002/ar.1092290418
SP  - A1
EP  - A97
PY  - 1991
ER  - 

TY  - JOUR
TI  - Subspeciality: Cardiovacular medicine
JO  - European Journal of Clinical Investigation
VL  - 31
IS  - s1
SN  - 0014-2972
UR  - https://doi.org/10.1111/j.1365-2362.2001.00001.x
DO  - doi:10.1111/j.1365-2362.2001.00001.x
SP  - 1
EP  - 44
PY  - 2001
ER  - 

TY  - JOUR
TI  - ISLH 2019 Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int J Lab Hem
VL  - 41
IS  - S2
SN  - 1751-5521
UR  - https://doi.org/10.1111/ijlh.13105
DO  - doi:10.1111/ijlh.13105
SP  - 1
EP  - 205
PY  - 2019
ER  - 

TY  - JOUR
TI  - Microvascular & Endothelial Physiology
JO  - The Journal of Physiology
JA  - The Journal of Physiology
VL  - 531
IS  - suppl
SN  - 0022-3751
UR  - https://doi.org/10.1111/j.1469-7793.2001.tb00362.x
DO  - doi:10.1111/j.1469-7793.2001.tb00362.x
SP  - 5P
EP  - 36P
PY  - 2001
ER  - 

TY  - JOUR
AU  - Sousa, Bruna R.
AU  - Parreira, Ricardo C.
AU  - Fonseca, Emerson A
AU  - Amaya, Maria J.
AU  - Tonelli, Fernanda M. P.
AU  - Lacerda, Samyra M. S. N.
AU  - Lalwani, Pritesh
AU  - Santos, Anderson K.
AU  - Gomes, Katia N.
AU  - Ulrich, Henning
AU  - Kihara, Alexandre H.
AU  - Resende, Rodrigo R.
TI  - Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications
JO  - Cytometry Part A
JA  - Cytometry
VL  - 85
IS  - 1
SN  - 1552-4922
UR  - https://doi.org/10.1002/cyto.a.22402
DO  - doi:10.1002/cyto.a.22402
SP  - 43
EP  - 77
KW  - umbilical cord blood
KW  - bone marrow
KW  - adipose-derived
KW  - placental and amniotic fluid
KW  - menstrual blood stem cells
KW  - differentiation
PY  - 2014
AB  - Abstract Stem cells are known for their capacity to self-renew and differentiate into at least one specialized cell type. Mesenchymal stem cells (MSCs) were isolated initially from bone marrow but are now known to exist in all vascularized organ or tissue in adults. MSCs are particularly relevant for therapy due to their simplicity of isolation and cultivation. The International Society for Cellular Therapy (ISCT) has proposed a set of standards to define hMSCs for laboratory investigations and preclinical studies: adherence to plastic in standard culture conditions; in vitro differentiation into osteoblasts, adipocytes, and chondroblasts; specific surface antigen expression in which ≥95% of the cells express the antigens recognized by CD105, CD73, and CD90, with the same cells lacking (≤2% positive) the antigens CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR. In this review we will take an historical overview of how umbilical cord blood, bone marrow, adipose-derived, placental and amniotic fluid, and menstrual blood stem cells, the major sources of human MSC, can be obtained, identified and how they are being used in clinical trials to cure and treat a very broad range of conditions, including heart, hepatic, and neurodegenerative diseases. An overview of protocols for differentiation into hepatocytes, cardiomyocytes, neuronal, adipose, chondrocytes, and osteoblast cells are highlighted. We also discuss a new source of stem cells, induced pluripotent stem cells (iPS cells) and some pathways, which are common to MSCs in maintaining their pluripotent state. ? 2013 International Society for Advancement of Cytometry
ER  - 

TY  - JOUR
TI  - Index
JO  - FEBS Letters
VL  - 178
IS  - S1
SN  - 0014-5793
UR  - https://doi.org/10.1016/0014-5793(84)81314-9
DO  - doi:10.1016/0014-5793(84)81314-9
SP  - 1
EP  - 78
PY  - 1984
ER  - 

C7  - pp. i-xxxv
TI  - Front Matter
SN  - 9781119940418
UR  - https://doi.org/10.1002/9781118683484.fmatter
DO  - doi:10.1002/9781118683484.fmatter
SP  - i-xxxv
PY  - 1984
AB  - Summary The prelims comprise: Half Title Title Copyright Dedicated About the Editor List of Contributors Acknowledgments Introduction
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - The FEBS Journal
VL  - 277
IS  - s1
SN  - 9781119940418
UR  - https://doi.org/10.1111/j.1742-4658.2010.07680.x
DO  - doi:10.1111/j.1742-4658.2010.07680.x
SP  - 37
EP  - 271
PY  - 2010
ER  - 

C7  - pp. 719-766
TI  - Specific Treatment of Aneurysmal Subarachnoid Haemorrhage
SN  - 9781405127660
UR  - https://doi.org/10.1002/9780470696361.ch14
DO  - doi:10.1002/9780470696361.ch14
SP  - 719-766
KW  - rebleeding
KW  - delayed cerebral ischaemia
KW  - acute hydrocephalus
KW  - haemorrhage
KW  - glasgow coma scale
PY  - 2010
AB  - Summary This chapter contains section titled: General principles Treatable causes of poor clinical condition on admission and their management General care Prevention of rebleeding Prevention of delayed cerebral ischaemia Management of rebleeding Management of delayed cerebral ischaemia Management of acute hydrocephalus Management of systemic complications Late sequelae and complications
ER  - 

TY  - JOUR
TI  - “Abstracts of the 77th Annual Meeting of the Japanese Cancer Association; 2018 Sept 27-29; Osaka, Japan” as Cancer Science, Supplement 2, Vol 109 (2018)
JO  - Cancer Science
JA  - Cancer Sci
VL  - 109
IS  - S2
SN  - 9781405127660
UR  - https://doi.org/10.1111/cas.13904
DO  - doi:10.1111/cas.13904
SP  - 1
EP  - 1444
PY  - 2018
ER  - 

TY  - JOUR
TI  - Section on Cardiology and Cardiac Surgery Full Abstracts from the AAP National Conference & Exhibition September 15–17, 2017—Chicago, IL
JO  - Congenital Heart Disease
JA  - Congenital Heart Disease
VL  - 12
IS  - 5
SN  - 9781405127660
UR  - https://doi.org/10.1111/chd.12538
DO  - doi:10.1111/chd.12538
SP  - 649
EP  - 691
PY  - 2017
ER  - 

TY  - JOUR
TI  - Oral and Poster Abstracts
JO  - Journal of Thrombosis and Haemostasis
VL  - 4
IS  - s1
SN  - 9781405127660
UR  - https://doi.org/10.1111/j.1538-7836.2006.02306.x
DO  - doi:10.1111/j.1538-7836.2006.02306.x
SP  - 67
EP  - 243
PY  - 2006
ER  - 

C7  - pp. 913-951
TI  - Subject Index
SN  - 9780470085851
UR  - https://doi.org/10.1002/9780470451496.indsub
DO  - doi:10.1002/9780470451496.indsub
SP  - 913-951
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Reproduction in Domestic Animals
VL  - 47
IS  - s4
SN  - 9780470085851
UR  - https://doi.org/10.1111/j.1439-0531.2012.02119.x
DO  - doi:10.1111/j.1439-0531.2012.02119.x
SP  - 416
EP  - 613
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
VL  - 97
IS  - S1
SN  - 9780470085851
UR  - https://doi.org/10.1111/j.1742-7843.2005.tb00015.x
DO  - doi:10.1111/j.1742-7843.2005.tb00015.x
SP  - 23
EP  - 128
PY  - 2005
ER  - 

TY  - JOUR
TI  - Moderated Posters
JO  - Transplant International
JA  - Transpl Int
VL  - 30
IS  - S2
SN  - 9780470085851
UR  - https://doi.org/10.1111/tri.13052
DO  - doi:10.1111/tri.13052
SP  - 370
EP  - 389
PY  - 2017
ER  - 

TY  - JOUR
AU  - Bialer, Meir
AU  - Johannessen, Svein I.
AU  - Levy, René H.
AU  - Perucca, Emilio
AU  - Tomson, Torbjörn
AU  - White, H. Steve
TI  - Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)
JO  - Epilepsia
JA  - Epilepsia
VL  - 58
IS  - 2
SN  - 9780470085851
UR  - https://doi.org/10.1111/epi.13634
DO  - doi:10.1111/epi.13634
SP  - 181
EP  - 221
KW  - Antiepileptic drugs
KW  - Drug development
KW  - Epilepsy
KW  - Epilepsy targets
PY  - 2017
AB  - Summary The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26?29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I?III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-d-glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE-217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec-butylpropylacetamide, FV-082, 1OP-2198, NAX 810-2, and SAGE-689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.
ER  - 

TY  - JOUR
TI  - Poster Session Group I – Blue TPS 1
JO  - Allergy
JA  - Allergy
VL  - 70
IS  - S101
SN  - 9780470085851
UR  - https://doi.org/10.1111/all.12719
DO  - doi:10.1111/all.12719
SP  - 290
EP  - 392
PY  - 2015
ER  - 

TY  - JOUR
TI  - From the new investigators sessions; From the oral free communications sessions; From the poster free communications sessions; From the selected invited speaker presentations
JO  - Ultrasound in Obstetrics & Gynecology
JA  - Ultrasound Obstet Gynecol
VL  - 20
IS  - S1
SN  - 9780470085851
UR  - https://doi.org/10.1046/j.1469-0705.20.s1.3.x
DO  - doi:10.1046/j.1469-0705.20.s1.3.x
SP  - 1
EP  - 89
PY  - 2002
ER  - 

TY  - JOUR
TI  - Index Volumes to 322–357
JO  - The Journal of Physiology
VL  - 357
IS  - index
SN  - 9780470085851
UR  - https://doi.org/10.1113/jphysiol.1984.sp015529
DO  - doi:10.1113/jphysiol.1984.sp015529
SP  - 471
EP  - 529
PY  - 1984
ER  - 
